SlideShare ist ein Scribd-Unternehmen logo
1 von 26
Downloaden Sie, um offline zu lesen
2014 Results
1
Cautionary statements:
This should be read in conjunction with the documents filed by Aviva plc (the “Company” or “Aviva”) with the United States Securities and Exchange Commission (“SEC”). This
announcement contains, and we may make other verbal or written “forward-looking statements” with respect to certain of Aviva’s plans and current goals and expectations relating to
future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words “believes”, “intends”, “expects”, “projects”, “plans”, “will,” “seeks”,
“aims”, “may”, “could”, “outlook”, “likely”, “target”, “goal”, “guidance”, “trends”, “future”, “estimates”, “potential” and “anticipates”, and words of similar meaning, are forward-looking.
By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those
indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the presentation include, but
are not limited to: the impact of ongoing difficult conditions in the global financial markets and the economy generally; the impact of simplifying our operating structure and activities; the
impact of various local political, regulatory and economic conditions; market developments and government actions regarding the sovereign debt crisis in Europe; the effect of credit
spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings,
on the value of our investments; changes in interest rates that may cause policyholders to surrender their contracts, reduce the value of our portfolio and impact our asset and liability
matching; the impact of changes in short or long term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates;
the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of
allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes
in, or restrictions on, our ability to initiate capital management initiatives or an acceleration of repayment of intercompany indebtedness; changes in or inaccuracy of assumptions in
pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; a cyclical
downturn of the insurance industry; the impact of natural and man-made catastrophic events on our business activities and results of operations; our reliance on information and
technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased
competition in the UK and in other countries where we have significant operations; the effect of the European Union’s “Solvency II” rules on our regulatory capital requirements; the
impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs (“DAC”) and acquired value of in-force business (“AVIF”); the impact of
recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment
securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and
human error or from external events; risks associated with arrangements with third parties, including joint ventures; our reliance on third-party distribution channels to deliver our
products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors
or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of
fluctuations in share price as a result of general market conditions or otherwise, including any as a result of the proposed acquisition of Friends Life; the effect of simplifying our
operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other
distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business, including
decreased demand for annuities in the UK due to proposed changes in UK law; the inability to protect our intellectual property; the effect of undisclosed liabilities, integration issues and
other risks associated with our acquisitions; and the timing/regulatory approval impact, integration risk and other uncertainties, such as non-realisation of expected benefits or diversion
of management attention and other resources, relating to announced acquisitions and pending disposals and relating to future acquisitions, combinations or disposals within relevant
industries, including specifically the proposed acquisition of Friends Life; the policies, decisions and actions of government or regulatory authorities in the UK, the EU, the US or
elsewhere, including the implementation of key legislation and regulation. For a more detailed description of these risks, uncertainties and other factors, please see Item 3d, “Risk
Factors”, and Item 5, “Operating and Financial Review and Prospects” in Aviva’s most recent Annual Report on Form 20-F as filed with the SEC on 24 March 2014 (and also Part II (Risk
Factors) of the prospectus published by Aviva on 19 January 2015 in relation to the proposed recommended all-share acquisition of Friends Life by Aviva). Aviva undertakes no obligation
to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this presentation are current only as
of the date on which such statements are made.
Disclaimer
2
Investment Thesis – “Cash flow plus growth”
Remittances from business units less
central and debt financing costs
Cash flow
1. Life Value of new business
2. GI Underwriting result
3. AI External net fund flows
Growth
3



















4
5
Progress on cash flow
6
Progress on growth
7
Transaction Rationale – Financial and strategic
•
• Leverage consistent with S&P AA rating –
no further need to de-lever
• £225 million of run rate synergies per
annum expected by end of 2017
• 30% increase in Aviva final dividend. Move
to c.2x operating EPS1 cover over the
medium term
• Secures leading position in our home market
• Brings c.5 million2 Friends Life customers to Aviva
• Adds significant scale and expertise to our
back book initiative
• Adds up to c.£70 billion of funds for
Aviva Investors
• Enables investment in our growth businesses
Financial Strategic
8
Update
• Integration planning well underway
• Management team announced on completion
• General Meeting 26th March
• Completion anticipated 13th April
9
10
11
12
•
•
•
•
•
13
•
•
•
14
•
•
•
•
•
15
•
•
•
•
16
•
•
•
•
•
•
17
18
19
20
%
21
Plan
22
23
24
25
Aviva
(As per Aviva disclosure)
Friends Life
(As per Friends Life disclosure)
26

Weitere ähnliche Inhalte

Was ist angesagt?

Aveda Energy investor presentation June 2014
Aveda Energy investor presentation June 2014Aveda Energy investor presentation June 2014
Aveda Energy investor presentation June 2014
AvedaEnergy
 
Aon IR Presentation August
Aon IR Presentation AugustAon IR Presentation August
Aon IR Presentation August
aoncorp
 

Was ist angesagt? (20)

Aveda Energy investor presentation June 2014
Aveda Energy investor presentation June 2014Aveda Energy investor presentation June 2014
Aveda Energy investor presentation June 2014
 
Q3 2014 Financial Highlights
Q3 2014 Financial HighlightsQ3 2014 Financial Highlights
Q3 2014 Financial Highlights
 
Investor Day 2013: Investing to Grow & Financials
Investor Day 2013: Investing to Grow & FinancialsInvestor Day 2013: Investing to Grow & Financials
Investor Day 2013: Investing to Grow & Financials
 
BI&P- Indusval - 1Q15 Results Presentation
BI&P- Indusval - 1Q15 Results PresentationBI&P- Indusval - 1Q15 Results Presentation
BI&P- Indusval - 1Q15 Results Presentation
 
Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015
 
Mark Cutifani’s presentation at the 2020 BofA Global Metals, Mining & Steel C...
Mark Cutifani’s presentation at the 2020 BofA Global Metals, Mining & Steel C...Mark Cutifani’s presentation at the 2020 BofA Global Metals, Mining & Steel C...
Mark Cutifani’s presentation at the 2020 BofA Global Metals, Mining & Steel C...
 
Aviva Plc 2016 Results
Aviva Plc 2016 ResultsAviva Plc 2016 Results
Aviva Plc 2016 Results
 
Q3 2013 Financial Highlights
Q3 2013 Financial HighlightsQ3 2013 Financial Highlights
Q3 2013 Financial Highlights
 
Q2 2013 Financial Highlights
Q2 2013 Financial HighlightsQ2 2013 Financial Highlights
Q2 2013 Financial Highlights
 
Q1 2014 Financial Hightlight Presentation
Q1 2014 Financial Hightlight PresentationQ1 2014 Financial Hightlight Presentation
Q1 2014 Financial Hightlight Presentation
 
Aimia Reports Second Quarter Results
Aimia Reports Second Quarter ResultsAimia Reports Second Quarter Results
Aimia Reports Second Quarter Results
 
3 q16 presentation final
3 q16 presentation   final3 q16 presentation   final
3 q16 presentation final
 
Winnebago Industries June 2020 NDR
Winnebago Industries June 2020 NDRWinnebago Industries June 2020 NDR
Winnebago Industries June 2020 NDR
 
Aksigorta - 2015 Q3 Financial Results Earnings Call Presentation
Aksigorta - 2015 Q3 Financial Results Earnings Call PresentationAksigorta - 2015 Q3 Financial Results Earnings Call Presentation
Aksigorta - 2015 Q3 Financial Results Earnings Call Presentation
 
Ir presentation august
Ir presentation   augustIr presentation   august
Ir presentation august
 
Ir presentation august
Ir presentation   augustIr presentation   august
Ir presentation august
 
Aon IR Presentation August
Aon IR Presentation AugustAon IR Presentation August
Aon IR Presentation August
 
Acquisition of Newmar
Acquisition of NewmarAcquisition of Newmar
Acquisition of Newmar
 
Bragg Gaming Group Investor Deck August 2021
Bragg Gaming Group Investor Deck August 2021Bragg Gaming Group Investor Deck August 2021
Bragg Gaming Group Investor Deck August 2021
 
Third Quarter 2016 Investor Presentation
Third Quarter 2016 Investor PresentationThird Quarter 2016 Investor Presentation
Third Quarter 2016 Investor Presentation
 

Andere mochten auch

metlife Investor Day 2008 Investments
metlife Investor Day 2008 Investmentsmetlife Investor Day 2008 Investments
metlife Investor Day 2008 Investments
finance5
 
metlife Investor Day 2008 International
metlife Investor Day 2008 Internationalmetlife Investor Day 2008 International
metlife Investor Day 2008 International
finance5
 
metlife Proxy Statement2007
metlife Proxy Statement2007metlife Proxy Statement2007
metlife Proxy Statement2007
finance5
 
Legal & General Company Profile
Legal & General Company ProfileLegal & General Company Profile
Legal & General Company Profile
Robert Peoples
 
Inspired Rewards - Power Point
Inspired Rewards - Power PointInspired Rewards - Power Point
Inspired Rewards - Power Point
Rachael Morse
 

Andere mochten auch (14)

[ARCHIVE] Aviva Working Lives report
[ARCHIVE] Aviva Working Lives report[ARCHIVE] Aviva Working Lives report
[ARCHIVE] Aviva Working Lives report
 
Middle class and Quality of life - Canada
Middle class and Quality of life - Canada Middle class and Quality of life - Canada
Middle class and Quality of life - Canada
 
A short corporate guide to Simplyhealth
A short corporate guide to SimplyhealthA short corporate guide to Simplyhealth
A short corporate guide to Simplyhealth
 
Why Metlife
Why MetlifeWhy Metlife
Why Metlife
 
metlife Investor Day 2008 Investments
metlife Investor Day 2008 Investmentsmetlife Investor Day 2008 Investments
metlife Investor Day 2008 Investments
 
Aviva's Working Lives report - Issue 2, February 2013
Aviva's Working Lives report - Issue 2, February 2013Aviva's Working Lives report - Issue 2, February 2013
Aviva's Working Lives report - Issue 2, February 2013
 
My new life in Canada
My new life in CanadaMy new life in Canada
My new life in Canada
 
metlife Investor Day 2008 International
metlife Investor Day 2008 Internationalmetlife Investor Day 2008 International
metlife Investor Day 2008 International
 
UK tax implications on Employee Benefits factsheet
UK tax implications on Employee Benefits factsheetUK tax implications on Employee Benefits factsheet
UK tax implications on Employee Benefits factsheet
 
metlife Proxy Statement2007
metlife Proxy Statement2007metlife Proxy Statement2007
metlife Proxy Statement2007
 
2012 Global Employee Benefit Survey Executive Summary
2012 Global Employee Benefit Survey   Executive Summary2012 Global Employee Benefit Survey   Executive Summary
2012 Global Employee Benefit Survey Executive Summary
 
Legal & General Company Profile
Legal & General Company ProfileLegal & General Company Profile
Legal & General Company Profile
 
Inspired Rewards - Power Point
Inspired Rewards - Power PointInspired Rewards - Power Point
Inspired Rewards - Power Point
 
Majeski v MetLife Webinar Presentation
Majeski v MetLife Webinar PresentationMajeski v MetLife Webinar Presentation
Majeski v MetLife Webinar Presentation
 

Ähnlich wie Aviva 2014 Results Presentation

Q2 2016
Q2 2016Q2 2016
Q2 2016
wuir
 
Q1 2015 earnings slides monday final review
Q1 2015 earnings slides monday final reviewQ1 2015 earnings slides monday final review
Q1 2015 earnings slides monday final review
investorjgwpt
 
Progyny JP Morgan Presentation January 2023.pdf
Progyny JP Morgan Presentation January 2023.pdfProgyny JP Morgan Presentation January 2023.pdf
Progyny JP Morgan Presentation January 2023.pdf
ssuser5105e0
 
Ir presentation february
Ir presentation   februaryIr presentation   february
Ir presentation february
aoncorp
 
3Q-2016-Investor-Presentation_Final_HR
3Q-2016-Investor-Presentation_Final_HR3Q-2016-Investor-Presentation_Final_HR
3Q-2016-Investor-Presentation_Final_HR
Erick Jimenez
 
January-2017-Investor-Presentation-FINAL
January-2017-Investor-Presentation-FINALJanuary-2017-Investor-Presentation-FINAL
January-2017-Investor-Presentation-FINAL
Erick Jimenez
 

Ähnlich wie Aviva 2014 Results Presentation (20)

Aviva 2017 Interim Results Analyst presentation
Aviva 2017 Interim Results Analyst presentationAviva 2017 Interim Results Analyst presentation
Aviva 2017 Interim Results Analyst presentation
 
Capital Markets Day 2016 presentation slides
Capital Markets Day 2016 presentation slidesCapital Markets Day 2016 presentation slides
Capital Markets Day 2016 presentation slides
 
2021_Q4 Earnings Supplemental Material_FINAL.pdf
2021_Q4 Earnings Supplemental Material_FINAL.pdf2021_Q4 Earnings Supplemental Material_FINAL.pdf
2021_Q4 Earnings Supplemental Material_FINAL.pdf
 
J.G. Wentworth Company Business Overview - Second Quarter 2015
J.G. Wentworth Company Business Overview - Second Quarter 2015J.G. Wentworth Company Business Overview - Second Quarter 2015
J.G. Wentworth Company Business Overview - Second Quarter 2015
 
JGW Business Overview – Jeffries Crossover Consumer Finance Summit
JGW Business Overview – Jeffries Crossover Consumer Finance Summit JGW Business Overview – Jeffries Crossover Consumer Finance Summit
JGW Business Overview – Jeffries Crossover Consumer Finance Summit
 
TCS FY Q1-23-Earnings-Presentation-FINAL 08-2023.pdf
TCS FY Q1-23-Earnings-Presentation-FINAL 08-2023.pdfTCS FY Q1-23-Earnings-Presentation-FINAL 08-2023.pdf
TCS FY Q1-23-Earnings-Presentation-FINAL 08-2023.pdf
 
Q2 2016
Q2 2016Q2 2016
Q2 2016
 
Q1 2015 earnings slides monday final review
Q1 2015 earnings slides monday final reviewQ1 2015 earnings slides monday final review
Q1 2015 earnings slides monday final review
 
Q4 Slides 020917
Q4 Slides 020917Q4 Slides 020917
Q4 Slides 020917
 
Progyny JP Morgan Presentation January 2023.pdf
Progyny JP Morgan Presentation January 2023.pdfProgyny JP Morgan Presentation January 2023.pdf
Progyny JP Morgan Presentation January 2023.pdf
 
BANC 1Q19 Earnings Presentation
BANC 1Q19 Earnings PresentationBANC 1Q19 Earnings Presentation
BANC 1Q19 Earnings Presentation
 
Aegon Corporate Venture Fund
Aegon Corporate Venture FundAegon Corporate Venture Fund
Aegon Corporate Venture Fund
 
Western Union Q3Y16 Earnings Presentation
Western Union Q3Y16 Earnings PresentationWestern Union Q3Y16 Earnings Presentation
Western Union Q3Y16 Earnings Presentation
 
Investor Relations Overview - February
Investor Relations Overview - FebruaryInvestor Relations Overview - February
Investor Relations Overview - February
 
September 2019 Investor Presentation
September 2019 Investor PresentationSeptember 2019 Investor Presentation
September 2019 Investor Presentation
 
Ir presentation february
Ir presentation   februaryIr presentation   february
Ir presentation february
 
3 q 2016 investor presentation final_hr
3 q 2016 investor presentation final_hr3 q 2016 investor presentation final_hr
3 q 2016 investor presentation final_hr
 
3Q-2016-Investor-Presentation_Final_HR
3Q-2016-Investor-Presentation_Final_HR3Q-2016-Investor-Presentation_Final_HR
3Q-2016-Investor-Presentation_Final_HR
 
January 2017 investor presentation final
January 2017 investor presentation finalJanuary 2017 investor presentation final
January 2017 investor presentation final
 
January-2017-Investor-Presentation-FINAL
January-2017-Investor-Presentation-FINALJanuary-2017-Investor-Presentation-FINAL
January-2017-Investor-Presentation-FINAL
 

Mehr von Aviva plc

Mehr von Aviva plc (20)

Aviva 2017 Interim Results announcement
Aviva 2017 Interim Results announcementAviva 2017 Interim Results announcement
Aviva 2017 Interim Results announcement
 
Aviva Plc 2016 Results Infographic
Aviva Plc 2016 Results InfographicAviva Plc 2016 Results Infographic
Aviva Plc 2016 Results Infographic
 
Aviva Plc 2016 Preliminary Results Announcement
Aviva Plc 2016 Preliminary Results AnnouncementAviva Plc 2016 Preliminary Results Announcement
Aviva Plc 2016 Preliminary Results Announcement
 
Aviva FY15 Analyst Pack
Aviva FY15 Analyst PackAviva FY15 Analyst Pack
Aviva FY15 Analyst Pack
 
Aviva 2015 Results Infographic
Aviva 2015 Results InfographicAviva 2015 Results Infographic
Aviva 2015 Results Infographic
 
6 things you probably don’t know about online insurance
6 things you probably don’t know about online insurance6 things you probably don’t know about online insurance
6 things you probably don’t know about online insurance
 
Aviva half year 2015 announcement
Aviva half year 2015 announcementAviva half year 2015 announcement
Aviva half year 2015 announcement
 
Investing to tackle climate risk
Investing to tackle climate riskInvesting to tackle climate risk
Investing to tackle climate risk
 
Aviva plc First Quarter 2015 Interim Management Statement
Aviva plc First Quarter 2015 Interim Management Statement Aviva plc First Quarter 2015 Interim Management Statement
Aviva plc First Quarter 2015 Interim Management Statement
 
Inflation drop gives over-55s an extra £1,032 a year in disposable income as ...
Inflation drop gives over-55s an extra £1,032 a year in disposable income as ...Inflation drop gives over-55s an extra £1,032 a year in disposable income as ...
Inflation drop gives over-55s an extra £1,032 a year in disposable income as ...
 
Road to reform: Driving out compensation culture
Road to reform: Driving out compensation cultureRoad to reform: Driving out compensation culture
Road to reform: Driving out compensation culture
 
Making your money last in retirement - Aviva's longevity report
Making your money last in retirement  - Aviva's longevity reportMaking your money last in retirement  - Aviva's longevity report
Making your money last in retirement - Aviva's longevity report
 
Making your money last in retirement - Aviva's longevity report
Making your money last in retirement  - Aviva's longevity reportMaking your money last in retirement  - Aviva's longevity report
Making your money last in retirement - Aviva's longevity report
 
Family Finances report - Dec 2014
Family Finances report - Dec 2014 Family Finances report - Dec 2014
Family Finances report - Dec 2014
 
Aviva plc Third Quarter 2014 Interim Management Statement
Aviva plc Third Quarter 2014 Interim Management StatementAviva plc Third Quarter 2014 Interim Management Statement
Aviva plc Third Quarter 2014 Interim Management Statement
 
Aviva Real Retirement Report Autumn 2014
Aviva Real Retirement Report  Autumn 2014Aviva Real Retirement Report  Autumn 2014
Aviva Real Retirement Report Autumn 2014
 
Half Year 2014 Results Announcement
Half Year 2014 Results AnnouncementHalf Year 2014 Results Announcement
Half Year 2014 Results Announcement
 
Road to Reform: Tackling the UK’s Compensation Culture July 2014
Road to Reform: Tackling the UK’s Compensation Culture July 2014Road to Reform: Tackling the UK’s Compensation Culture July 2014
Road to Reform: Tackling the UK’s Compensation Culture July 2014
 
Aviva plc annual report and accounts 2013
Aviva plc annual report and accounts 2013Aviva plc annual report and accounts 2013
Aviva plc annual report and accounts 2013
 
The Aviva Real Retirement Report - Spring 2014
The Aviva Real Retirement Report - Spring 2014The Aviva Real Retirement Report - Spring 2014
The Aviva Real Retirement Report - Spring 2014
 

Kürzlich hochgeladen

FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
Cocity Enterprises
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
samsungultra782445
 
Economics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjwEconomics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjw
mordockmatt25
 
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnLaw of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
TintoTom3
 
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
hyt3577
 
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
Health
 

Kürzlich hochgeladen (20)

Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdfSeeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
 
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
 
Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...
 
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
 
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & RequirementsExplore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
 
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
 
Strategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate PresentationStrategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate Presentation
 
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
 
Economics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjwEconomics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjw
 
Technology industry / Finnish economic outlook
Technology industry / Finnish economic outlookTechnology industry / Finnish economic outlook
Technology industry / Finnish economic outlook
 
Shrambal_Distributors_Newsletter_May-2024.pdf
Shrambal_Distributors_Newsletter_May-2024.pdfShrambal_Distributors_Newsletter_May-2024.pdf
Shrambal_Distributors_Newsletter_May-2024.pdf
 
Bhubaneswar🌹Ravi Tailkes ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
Bhubaneswar🌹Ravi Tailkes  ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...Bhubaneswar🌹Ravi Tailkes  ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
Bhubaneswar🌹Ravi Tailkes ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
 
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnLaw of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
 
7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator Options7 tips trading Deriv Accumulator Options
7 tips trading Deriv Accumulator Options
 
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budgetCall Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
 
Responsible Finance Principles and Implication
Responsible Finance Principles and ImplicationResponsible Finance Principles and Implication
Responsible Finance Principles and Implication
 
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
QATAR Pills for Abortion -+971*55*85*39*980-in Dubai. Abu Dhabi.
 
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
 
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
+97470301568>>buy weed in qatar,buy thc oil in qatar doha>>buy cannabis oil i...
 

Aviva 2014 Results Presentation

  • 2. Cautionary statements: This should be read in conjunction with the documents filed by Aviva plc (the “Company” or “Aviva”) with the United States Securities and Exchange Commission (“SEC”). This announcement contains, and we may make other verbal or written “forward-looking statements” with respect to certain of Aviva’s plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words “believes”, “intends”, “expects”, “projects”, “plans”, “will,” “seeks”, “aims”, “may”, “could”, “outlook”, “likely”, “target”, “goal”, “guidance”, “trends”, “future”, “estimates”, “potential” and “anticipates”, and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the presentation include, but are not limited to: the impact of ongoing difficult conditions in the global financial markets and the economy generally; the impact of simplifying our operating structure and activities; the impact of various local political, regulatory and economic conditions; market developments and government actions regarding the sovereign debt crisis in Europe; the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; changes in interest rates that may cause policyholders to surrender their contracts, reduce the value of our portfolio and impact our asset and liability matching; the impact of changes in short or long term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives or an acceleration of repayment of intercompany indebtedness; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events on our business activities and results of operations; our reliance on information and technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK and in other countries where we have significant operations; the effect of the European Union’s “Solvency II” rules on our regulatory capital requirements; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs (“DAC”) and acquired value of in-force business (“AVIF”); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events; risks associated with arrangements with third parties, including joint ventures; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of fluctuations in share price as a result of general market conditions or otherwise, including any as a result of the proposed acquisition of Friends Life; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business, including decreased demand for annuities in the UK due to proposed changes in UK law; the inability to protect our intellectual property; the effect of undisclosed liabilities, integration issues and other risks associated with our acquisitions; and the timing/regulatory approval impact, integration risk and other uncertainties, such as non-realisation of expected benefits or diversion of management attention and other resources, relating to announced acquisitions and pending disposals and relating to future acquisitions, combinations or disposals within relevant industries, including specifically the proposed acquisition of Friends Life; the policies, decisions and actions of government or regulatory authorities in the UK, the EU, the US or elsewhere, including the implementation of key legislation and regulation. For a more detailed description of these risks, uncertainties and other factors, please see Item 3d, “Risk Factors”, and Item 5, “Operating and Financial Review and Prospects” in Aviva’s most recent Annual Report on Form 20-F as filed with the SEC on 24 March 2014 (and also Part II (Risk Factors) of the prospectus published by Aviva on 19 January 2015 in relation to the proposed recommended all-share acquisition of Friends Life by Aviva). Aviva undertakes no obligation to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this presentation are current only as of the date on which such statements are made. Disclaimer 2
  • 3. Investment Thesis – “Cash flow plus growth” Remittances from business units less central and debt financing costs Cash flow 1. Life Value of new business 2. GI Underwriting result 3. AI External net fund flows Growth 3
  • 5. 5
  • 8. Transaction Rationale – Financial and strategic • • Leverage consistent with S&P AA rating – no further need to de-lever • £225 million of run rate synergies per annum expected by end of 2017 • 30% increase in Aviva final dividend. Move to c.2x operating EPS1 cover over the medium term • Secures leading position in our home market • Brings c.5 million2 Friends Life customers to Aviva • Adds significant scale and expertise to our back book initiative • Adds up to c.£70 billion of funds for Aviva Investors • Enables investment in our growth businesses Financial Strategic 8 Update • Integration planning well underway • Management team announced on completion • General Meeting 26th March • Completion anticipated 13th April
  • 9. 9
  • 10. 10
  • 11. 11
  • 12. 12
  • 18. 18
  • 19. 19
  • 20. 20
  • 22. 22
  • 23. 23
  • 24. 24
  • 25. 25
  • 26. Aviva (As per Aviva disclosure) Friends Life (As per Friends Life disclosure) 26